Advertisement

Drugs Used in Parasomnia

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. American Academy of Sleep Medicine. International classification of sleep disorders-third edition (ICSD-3). Darien (Illinois); 2014.

        • Stallman H.M.
        • Kohler M.
        Prevalence of sleepwalk ing: a systematic review and meta-analysis.
        PLoS One. 2016; 11: e0164769
        • Derry C.P.
        • Harvey A.S.
        • Walker M.C.
        • et al.
        NREM arousal parasomnias and their distinction from nocturnal frontal lobe epilepsy: a video EEG anal ysis.
        Sleep. 2009; 32: 1637-1644
        • Howell M.J.
        Parasomnias: an updated review.
        Neu-rotherapeutics. 2012; 9: 753-775
        • Zadra A.
        • Desautels A.
        • Petit D.
        • et al.
        Somnambu lism: clinical aspects and pathophysiological hy potheses.
        Lancet Neurol. 2013; 12: 285-294
        • Siclari F.
        • Khatami R.
        • Urbaniok F.
        • et al.
        Violence in sleep.
        Brain. 2010; 133: 3494-3509
        • Lopez R.
        • Jaussent I.
        • Scholz S.
        • et al.
        Functional impairment in adult sleepwalkers: a case-control study.
        Sleep. 2013; 36: 345-351
        • Harris M.
        • Grunstein R.R.
        Treatments for somnambu lism in adults: assessing the evidence.
        Sleep Med Rev. 2009; 13: 295-297
        • Attarian H.
        • Zhu L.
        Treatment options for disorders of arousal: a case series.
        Int J Neurosci. 2013; 123: 623-625
        • Arnulf I.
        • Zhang B.
        • Uguccioni G.
        • et al.
        A scale for assessing the severity of arousal disorders.
        Sleep. 2014; 37: 127-136
        • Attarian H.
        Treatment options for parasomnias.
        Neurol Clin. 2010; 28: 1089-1106
        • Tinuper P.
        • Bisulli F.
        • Provini F.
        The parasomnias: mech-anisms and treatment: the parasomnias: mecha- nisms and treatment.
        Epilepsia. 2012; 53: 12-19
        • Kotagal S.
        Treatment of dyssomnias and parasom nias in childhood.
        Curr Treat Options Neurol. 2012; 14: 630-649
        • Galbiati A.
        • Rinaldi F.
        • Giora E.
        • et al.
        Behavioural and cognitive-behavioural treatments of parasomnias.
        Behav Neurol. 2015; 2015: 786928
        • Guilleminault C.
        • Kirisoglu C.
        • Bao G.
        • et al.
        Adult chronic sleepwalking and its treatment based on polysomnography.
        Brain. 2005; 128: 1062-1069
        • Cochen De Cock V.
        Sleepwalking.
        Curr Treat Op-tions Neurol. 2016; 18: 6
        • Rudolph U.
        • Mohler H.
        GABA-based therapeutic approaches: GABAA receptor subtype functions.
        Curr Opin Pharmacol. 2006; 6: 18-23
        • Dolder C.R.
        • Nelson M.H.
        Hypnosedative-induced complex behaviours: incidence, mechanisms and management.
        CNS Drugs. 2008; 22: 1021-1036
        • Mason T.B.A.
        • Pack A.I.
        Sleep terrors in childhood.
        J Pediatr. 2005; 147: 388-392
        • Allen R.M.
        Attenuation of drug-induced anxiety dreams and pavor nocturnus by benzodiazepines.
        J Clin Psychiatry. 1983; 44: 106-108
        • Schenck C.H.
        • Milner D.M.
        • Hurwitz T.D.
        • et al.
        A polysomnographic and clinical report on sleep-related injury in 100 adult patients.
        Am J Psychiatry. 1989; 146: 1166-1173
        • Schenck C.H.
        • Mahowald M.W.
        Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults.
        Am J Med. 1996; 100: 333-337
        • Goldbloom D.
        • Chouinard G.
        Clonazepam in the treatment of neuroleptic-induced somnambulism.
        Am J Psychiatry. 1984; 141: 1486
        • Schenck C.H.
        • Mahowald M.W.
        A polysomnographi-cally documented case of adult somnambulism with long-distance automobile driving and frequent nocturnal violence: parasomnia with continuing danger as a noninsane automatism?.
        Sleep. 1995; 18: 765-772
        • Remulla A.
        • Guilleminault C.
        Somnambulism (sleep walking).
        Expert Opin Pharmacother. 2004; 5: 2069-2074
        • Reid W.H.
        • Haffke E.A.
        • Chu C.C.
        Diazepam in intrac-table sleepwalking: a pilot study.
        Hillside J Clin Psychiatry. 1984; 6: 49-55
        • Berlin R.M.
        • Qayyum U.
        Sleepwalking: diagnosis and treatment through the life cycle.
        Psychoso-matics. 1986; 27: 755-760
        • Kavey N.B.
        • Whyte J.
        • Resor S.R.
        • et al.
        Somnambu lism in adults.
        Neurology. 1990; 40: 749-752
        • Kierlin L.
        • Littner M.R.
        Parasomnias and antidepres-sant therapy: a review of the literature.
        Front Psychiatry. 2011; 2: 71
        • Cooper A.J.
        Treatment of coexistent night-terrors and somnambulism in adults with imipramine and diazepam.
        J Clin Psychiatry. 1987; 48: 209-210
        • Balon R.
        Sleep terror disorder and insomnia treated with trazodone: a case report.
        Ann Clin Psychiatry. 1994; 6: 161-163
        • Wilson S.J.
        • Lillywhite A.R.
        • Potokar J.P.
        • et al.
        Adult night terrors and paroxetine.
        Lancet. 1997; 350: 185
        • Frölich Alfred Wiater Gerd Lehmkuhl J.
        Successful treatment of severe parasomnias with paroxetine in a 12-year-old boy.
        Int J Psychiatry Clin Pract. 2001; 5: 215-218
        • Lillywhite A.R.
        • Wilson S.J.
        • Nutt D.J.
        Successful treat ment of night terrors and somnambulism with par oxetine.
        Br J Psychiatry. 1994; 164: 551-554
        • Kawashima T.
        • Yamada S.
        Paroxetine-induced som-nambulism.
        J Clin Psychiatry. 2003; 64: 483
        • Xie Z.
        • Chen F.
        • Li W.A.
        • et al.
        A review of sleep dis orders and melatonin.
        Neurol Res. 2017; 39: 559-565
        • Jan J.E.
        • Freeman R.D.
        Melatonin therapy for circa-dian rhythm sleep disorders in children with mul tiple disabilities: what have we learned in the last decade?.
        Dev Med Child Neurol. 2004; 46: 776-782
        • Jan J.E.
        • Freeman R.D.
        • Wasdell M.B.
        • et al.
        A child with severe night terrors and sleep-walking re-sponds to melatonin therapy.
        Dev Med Child Neurol. 2004; 46: 789
        • Ozcan O.
        • Donmez Y.E.
        Melatonin treatment for childhood sleep terror.
        J Child Adolesc Psychopharmacol. 2014; 24: 528-529
        • Bruni O.
        • Ferri R.
        • Miano S.
        • et al.
        l-5-Hydroxytrypto-phan treatment of sleep terrors in children.
        Eur J Pediatr. 2004; 163: 402-407
        • Sasayama D.
        • Washizuka S.
        • Honda H.
        Effective treatment of night terrors and sleepwalking with ra-melteon.
        J Child Adolesc Psychopharmacol. 2016; 26: 948
        • Winkelman J.W.
        • Johnson E.A.
        • Richards L.M.
        Sleep- related eating disorder.
        Handb Clin Neurol. 2011; 98: 577-585
        • Inoue Y.
        Sleep-related eating disorder and its asso ciated conditions: clinical implication of SRED.
        Psychiatry Clin Neurosci. 2015; 69: 309-320
        • Howell M.J.
        • Schenck C.H.
        Restless nocturnal eating: a common feature of Willis-Ekbom Syndrome (RLS).
        J Clin Sleep Med. 2012; 8: 413-419
        • Auger R.R.
        Sleep-related eating disorders.
        Psychia-try (Edgmont). 2006; 3: 64
        • Brion A.
        • Flamand M.
        • Oudiette D.
        • et al.
        Sleep- related eating disorder versus sleepwalking: a controlled study.
        Sleep Med. 2012; 13: 1094-1101
        • Chiaro G.
        • Caletti M.T.
        • Provini F.
        Treatment of sleep- related eating disorder.
        Curr Treat Options Neurol. 2015; 17: 361
        • Howell M.J.
        • Schenck C.H.
        Treatment of nocturnal eating disorders.
        Curr Treat Options Neurol. 2009; 11: 333-339
        • Provini F.
        • Albani F.
        • Vetrugno R.
        • et al.
        A pilot double-blind placebo-controlled trial of low-dose prami pexole in sleep-related eating disorder.
        Eur J Neurol. 2005; 12: 432-436
        • Santin J.
        • Mery V.
        • Elso M.J.
        • et al.
        Sleep-related eating disorder: a descriptive study in Chilean pa tients.
        Sleep Med. 2014; 15: 163-167
        • Schenck C.H.
        • Hurwitz T.D.
        • O'Connor K.A.
        • et al.
        Addi-tional categories of sleep-related eating disorders and the current status of treatment.
        Sleep. 1993; 16: 457-466
        • Miyaoka T.
        • Yasukawa R.
        • Tsubouchi K.
        • et al.
        Suc cessful treatment of nocturnal eating/drinking syndrome with selective serotonin reuptake in-hibitors.
        Int Clin Psychopharmacol. 2003; 18: 175-177
        • Martinez-Salio A.
        • Soler-Algarra S.
        • Calvo-Garcia I.
        • et al.
        Nocturnal sleep-related eating disorder that responds to topiramate.
        Rev Neurol. 2007; 45 ([in Spanish]): 276-279
        • Winkelman J.W.
        Treatment of nocturnal eating syn-drome and sleep-related eating disorder with topir amate.
        Sleep Med. 2003; 4: 243-246
        • Winkelman J.W.
        Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series.
        J Clin Psychiatry. 2006; 67: 1729-1734
        • Wilkes J.J.
        • Nelson E.
        • Osborne M.
        • et al.
        Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats.
        Am J Physiol Endocrinol Metab. 2005; 288: E617-E624
        • Zapp A.A.
        • Fischer E.C.
        • Deuschle M.
        The effect of agomelatine and melatonin on sleep-related eating: a case report.
        J Med Case Rep. 2017; 11: 275
        • Comella C.L.
        • Nardine T.M.
        • Diederich N.J.
        • et al.
        Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease.
        Neurology. 1998; 51: 526-529
        • McCarter S.J.
        • St Louis E.K.
        • Boswell C.L.
        • et al.
        Fac-tors associated with injury in REM sleep behavior disorder.
        Sleep Med. 2014; 15: 1332-1338
        • Olson E.J.
        • Boeve B.F.
        • Silber M.H.
        Rapid eye move-ment sleep behaviour disorder: demographic, clin-ical and laboratory findings in 93 cases.
        Brain J Neurol. 2000; 123: 331-339
        • Postuma R.B.
        • Gagnon J.-F.
        • Tuineaig M.
        • et al.
        Antide-pressants and REM sleep behavior disorder: iso-lated side effect or neurodegenerative signal?.
        Sleep. 2013; 36: 1579-1585
        • Aurora R.N.
        • Zak R.S.
        • Maganti R.K.
        • et al.
        Best prac-tice guide for the treatment of REM sleep behavior disorder (RBD).
        J Clin Sleep Med. 2010; 6: 85-95
        • Schenck C.H.
        • Bundlie S.R.
        • Ettinger M.G.
        • et al.
        Chronic behavioral disorders of human REM sleep: a new category of parasomnia.
        Sleep. 1986; 9: 293-308
        • Li S.X.
        • Lam S.P.
        • Zhang J.
        • et al.
        A prospective, natu ralistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder.
        Sleep Med. 2016; 21: 114-120
        • McCarter S.J.
        • Boswell C.L.
        • St Louis E.K.
        • et al.
        Treat ment outcomes in REM sleep behavior disorder.
        Sleep Med. 2013; 14: 237-242
        • Terzaghi M.
        • Sartori I.
        • Rustioni V.
        • et al.
        Sleep disor ders and acute nocturnal delirium in the elderly: a comorbidity not to be overlooked.
        Eur J Intern Med. 2014; 25: 350-355
        • Kunz D.
        • Mahlberg R.
        A two-part, double-blind, pla-cebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder.
        J Sleep Res. 2010; 19: 591-596
        • Kunz D.
        • Bes F.
        Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation.
        Mov Disord. 1999; 14: 507-511
        • Boeve B.F.
        • Silber M.H.
        • Ferman T.J.
        Melatonin for treatment of REM sleep behavior disorder in neuro-logic disorders: results in 14 patients.
        Sleep Med. 2003; 4: 281-284
        • Nomura T.
        • Kawase S.
        • Watanabe Y.
        • et al.
        Use of ra- melteon for the treatment of secondary REM sleep behavior disorder.
        Intern Med. 2013; 52: 2123-2126
        • Esaki Y.
        • Kitajima T.
        • Koike S.
        • et al.
        An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder.
        J Clin Sleep Med. 2016; 12: 689-693
        • St. Louis E.K.
        • McCarter S.J.
        • Boeve B.F.
        Ramelteon for idiopathic REM sleep behavior disorder: impli cations for pathophysiology and future treatment trials.
        J Clin Sleep Med. 2016; 12: 643-645
        • Bonakis A.
        • Economou N.-T.
        • Papageorgiou S.G.
        • et al.
        Agomelatine may improve REM sleep behavior dis order symptoms.
        J Clin Psychopharmacol. 2012; 32: 732-734
        • Fantini M.L.
        • Gagnon J.-F.
        • Filipini D.
        • et al.
        The effects of pramipexole in REM sleep behavior disorder.
        Neurology. 2003; 61: 1418-1420
        • Sasai T.
        • Matsuura M.
        • Inoue Y.
        Factors associated with the effect of pramipexole on symptoms of idio pathic REM sleep behavior disorder.
        Parkinsonism Relat Disord. 2013; 19: 153-157
        • Schmidt M.H.
        • Koshal V.B.
        • Schmidt H.S.
        Use of pra mipexole in REM sleep behavior disorder: results from a case series.
        Sleep Med. 2006; 7: 418-423
        • Kumru H.
        • Iranzo A.
        • Carrasco E.
        • et al.
        Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
        Sleep. 2008; 31: 1418-1421
        • McCarley R.W.
        Neurobiology of REM and NREM sleep.
        Sleep Med. 2007; 8: 302-330
        • Fernandez H.H.
        • Wu C.-K.
        • Ott B.R.
        Pharmacotherapy of dementia with Lewy bodies.
        Expert Opin Pharmacother. 2003; 4: 2027-2037
        • Terzaghi M.
        • Rustioni V.
        • Manni R.
        • et al.
        Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: immediate efficacy of rivastig- mine.
        Mov Disord. 2010; 25: 647-649
        • Brunetti V.
        • Losurdo A.
        • Testani E.
        • et al.
        Rivastigmine for refractory REM behavior disorder in mild cogni tive impairment.
        Curr Alzheimer Res. 2014; 11: 267-273
        • Di Giacopo R.
        • Fasano A.
        • Quaranta D.
        • et al.
        Riva- stigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease.
        Mov Disord. 2012; 27: 559-561
        • Massironi G.
        • Galluzzi S.
        • Frisoni G.B.
        Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies.
        Int Psychogeriatr. 2003; 15: 377-383
        • Ringman J.M.
        • Simmons J.H.
        Treatment of REM sleep behavior disorder with donepezil: a report of three cases.
        Neurology. 2000; 55: 870-871
        • Yeh S.-B.
        • Yeh P.-Y.
        • Schenck C.H.
        Rivastigmine- induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease.
        J Clin Sleep Med. 2010; 6: 192-195
        • Babson K.A.
        • Sottile J.
        • Morabito D.
        Cannabis, can- nabinoids, and sleep: a review of the literature.
        Curr Psychiatry Rep. 2017; 19: 23
        • Chagas M.H.N.
        • Eckeli A.L.
        • Zuardi A.W.
        • et al.
        Cannabi- diol can improve complex sleep-related behaviours associated with rapid eye movement sleep behav iour disorder in Parkinson's disease patients: a case series.
        J Clin Pharm Ther. 2014; 39: 564-566
        • Anderson K.N.
        • Shneerson J.M.
        Drug treatment of REM sleep behavior disorder: the use of drug ther apies other than clonazepam.
        J Clin Sleep Med. 2009; 5: 235-239
        • Bonakis A.
        • Howard R.S.
        • Ebrahim I.O.
        • et al.
        REM sleep behaviour disorder (RBD) and its associa tions in young patients.
        Sleep Med. 2009; 10: 641-645
        • Jung Y.
        • St Louis E.K.
        Treatment of REM sleep behavior disorder.
        Curr Treat Options Neurol. 2016; 18: 50
        • Moghadam K.K.
        • Pizza F.
        • Primavera A.
        • et al.
        Sodium oxybate for idiopathic REM sleep behavior disor der: a report on two patients.
        Sleep Med. 2017; 32: 16-21
        • Shneerson J.M.
        Successful treatment of REM sleep behavior disorder with sodium oxybate.
        Clin Neuropharmacol. 2009; 32: 158-159
        • Detweiler M.B.
        • Pagadala B.
        • Candelario J.
        • et al.
        Treatment of post-traumatic stress disorder night- mares at a Veterans Affairs medical center.
        J Clin Med. 2016; 5: E117
        • Jeffreys M.
        • Capehart B.
        • Friedman M.J.
        Pharmaco- therapy for posttraumatic stress disorder: review with clinical applications.
        J Rehabil Res Dev. 2012; 49: 703-715
        • Miller K.E.
        • Brownlow J.A.
        • Woodward S.
        • et al.
        Sleep and dreaming in posttraumatic stress disorder.
        Curr Psychiatry Rep. 2017; 19: 71
        • George K.C.
        • Kebejian L.
        • Ruth L.J.
        • et al.
        Meta-analysis of the efficacy and safety of prazosin versus placebo for the treatment of nightmares and sleep distur bances in adults with posttraumatic stress disorder.
        J Trauma Dissociation. 2016; 17: 494-510
        • Kung S.
        • Espinel Z.
        • Lapid M.I.
        Treatment of night mares with prazosin: a systematic review.
        Mayo Clin Proc. 2012; 87: 890-900
        • Raskind M.A.
        • Peterson K.
        • Williams T.
        • et al.
        A trial of prazosin for combat trauma PTSD with night- mares in active-duty soldiers returned from Iraq and Afghanistan.
        Am J Psychiatry. 2013; 170: 1003-1010
        • Hudson S.M.
        • Whiteside T.E.
        • Lorenz R.A.
        • et al.
        Prazo sin for the treatment of nightmares related to post traumatic stress disorder: a review of the literature.
        Prim Care Companion CNS Disord. 2012; 14
        • Khachatryan D.
        • Groll D.
        • Booij L.
        • et al.
        Prazosin for treating sleep disturbances in adults with posttrau- matic stress disorder: a systematic review and meta-analysis of randomized controlled trials.
        Gen Hosp Psychiatry. 2016; 39: 46-52
        • Cameron C.
        • Watson D.
        • Robinson J.
        Use of a syn- thetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.
        J Clin Psychopharmacol. 2014; 34: 559-564
        • Fraser G.A.
        The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).
        CNS Neu-rosci Ther. 2009; 15: 84-88
        • Jetly R.
        • Heber A.
        • Fraser G.
        • et al.
        The efficacy of na- bilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary ran- domized, double-blind, placebo-controlled cross over design study.
        Psychoneuroendocrinology. 2015; 51: 585-588
        • Roitman P.
        • Mechoulam R.
        • Cooper-Kazaz R.
        • et al.
        Preliminary, open-label, pilot study of add-on oral D9-tetrahydrocannabinol in chronic post-traumatic stress disorder.
        Clin Drug Investig. 2014; 34: 587-591
        • Guilleminault C.
        • Raynal D.
        • Takahashi S.
        • et al.
        Eval- uation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydro- chloride.
        Acta Neurol Scand. 1976; 54: 71-87
        • Hishikawa Y.
        • Ida H.
        • Nakai K.
        • et al.
        Treatment of narcolepsy with imipramine (tofranil) and desme- thylimipramine (pertofran).
        J Neurol Sci. 1966; 3: 453-461
        • Mitler M.M.
        • Hajdukovic R.
        • Erman M.
        • et al.
        Narco lepsy.
        J Clin Neurophysiol. 1990; 7: 93-118
        • Koran L.M.
        • Raghavan S.
        Fluoxetine for isolated sleep paralysis.
        Psychosomatics. 1993; 34: 184-187
        • Schrader H.
        • Kayed K.
        • Bendixen Markset A.C.
        • et al.
        The treatment of accessory symptoms in narco- lepsy: a double-blind cross-over study of a selec- tive serotonin re-uptake inhibitor (femoxetine) versus placebo.
        Acta Neurol Scand. 1986; 74: 297-303
        • Abad V.C.
        • Guilleminault C.
        New developments in the management of narcolepsy.
        Nat Sci Sleep. 2017; 9: 39-57
        • Frese A.
        • Summ O.
        • Evers S.
        Exploding head syn- drome: six new cases and review of the literature.
        Cephalalgia. 2014; 34: 823-827
        • Sharpless B.A.
        Exploding head syndrome.
        Sleep Med Rev. 2014; 18: 489-493
        • Sachs C.
        • Svanborg E.
        The exploding head syn- drome: polysomnographic recordings and thera- peutic suggestions.
        Sleep. 1991; 14: 263-266
        • Chakravarty A.
        Exploding Head syndrome: report of two new cases.
        Cephalalgia. 2008; 28: 399-400
        • Jacome D.E.
        Exploding head syndrome and idio- pathic stabbing headache relieved by nifedipine.
        Cephalalgia Int J Headache. 2001; 21: 617-618
        • Palikh G.M.
        • Vaughn B.V.
        Topiramate responsive ex- ploding head syndrome.
        J Clin Sleep Med. 2010; 6: 382-383
        • Harari M.D.
        Nocturnal enuresis: nocturnal enuresis.
        J Paediatr Child Health. 2013; 49: 264-271
        • Jain S.
        • Bhatt G.C.
        Advances in the management of primary monosymptomatic nocturnal enuresis in children.
        Paediatr Int Child Health. 2016; 36: 7-14
        • Kuwertz-Broking E.
        • von Gontard A.
        Clinical man agement of nocturnal enuresis.
        Pediatr Nephrol. 2018; 33: 1145-1154
        • Caldwell P.H.Y.
        • Deshpande A.V.
        • Gontard A.V.
        Man agement of nocturnal enuresis.
        BMJ. 2013; 347: f6259
        • Glazener C.M.A.
        • Evans J.H.C.
        • Peto R.E.
        Alarm inter- ventions for nocturnal enuresis in children.
        Cohrane Database Syst Rev. 2005; 2: CD002911
        • Hjalmas K.
        • Arnold T.
        • Bower W.
        • et al.
        Nocturnal enuresis: an international evidence based man- agement strategy.
        J Urol. 2004; 171: 2545-2561
        • Robson W.L.M.
        • Leung A.K.C.
        • Norgaard J.P.
        The comparative safety of oral versus intranasal des- mopressin for the treatment of children with nocturnal enuresis.
        J Urol. 2007; 178: 24-30
        • Neveus T.
        • Eggert P.
        • Evans J.
        • et al.
        Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society.
        J Urol. 2010; 183: 441-447
        • Glazener C.M.
        • Evans J.H.
        Desmopressin for nocturnal enuresis in children.
        Cochrane Database Syst Rev. 2002; 3: CD002112
        • Neveus T.
        Nocturnal enuresis-theoretic back ground and practical guidelines.
        Pediatr Nephrol. 2011; 26: 1207-1214
        • Caldwell P.H.Y.
        • Sureshkumar P.
        • Wong W.C.F.
        Tricyclic and related drugs for nocturnal enuresis in children.
        Cochrane Database Syst Rev. 2016; 1: CD002117
      2. International Consultation on Incontinence Abrams P. Cardozo L. Incontinence. 4th edition. Health Publication, Paris2009
        • Hoebeke P.
        • De Pooter J.
        • De Caestecker K.
        • et al.
        Solifenacin for therapy resistant overactive bladder.
        J Urol. 2009; 182: 2040-2044
        • Raes A.
        • Hoebeke P.
        • Segaert I.
        • et al.
        Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder.
        Eur Urol. 2004; 45: 240-244
        • Deshpande A.V.
        • Caldwell P.H.Y.
        • Sureshkumar P.
        Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics).
        Cochrane Database Syst Rev. 2012; 12: CD002238
        • Yu J.
        • Yan Z.
        • Zhou S.
        • et al.
        Desmopressin plus anti- cholinergic agent in the treatment of nocturnal enuresis: a meta-analysis.
        Exp Ther Med. 2017; 14: 2875-2884